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A B S T R A C T
Background: The efﬁcacy of statin therapy may be lost or vary with reduction in compliance and intensity
of statin therapy.
Objective: To study and correlate the quantitative effect of compliance on lipid proﬁle and 3-hydroxyl-3-
methylglutaryl coenzyme A reductase (HMGCoA-R) levels in dyslipidemic patients.
Methods: Compliance to different intensity of statin therapy assessed by pill count was correlated with
serum levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density
lipoprotein-cholesterol (HDL-C), triglycerides (TG), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB)
and HMGCoA-R.
Results: Out of 200 patients, 160 received moderate intensity statin therapy whereas 40 were on high
intensity statin therapy. The overall mean compliance of patients was 56.7%. The compliance of patients
on moderate intensity statin therapy was higher (56.8%) than those on high intensity (56.4%) (p = 0.92).
There was signiﬁcant inverse correlation (p < 0.05) between compliance and TC, TG, LDL-C and
HMGCoA-R levels and positive correlation (p < 0.05) with HDL-C levels. The mean serum HMGCoA-R
levels did not fall below 9–10 ng/mL when compliance to either moderate or high intensity statin
therapy was increased above 60%.
Conclusions: It is appropriate to improve the compliance to existing statin therapy than switching over to
higher intensity statin therapy. Estimation of HMGCoA-R levels may be explored as a surrogate marker to
monitor and assess the compliance of patients to statin therapy.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Dyslipidemia is a major risk factor for cardiovascular diseases
(CVD) contributing to more than 25% of all deaths worldwide.1,2
Indians are more prone to CVD due to higher prevalence of
dyslipidemia (45.6%) as compared to the Western world (29.3%).3,4
American College of Cardiology/American Heart Association
(ACC/AHA) Guidelines 2013 recommended high dose of statin
therapy for patients (21 years of age) having any form of CVD
or serum low density lipoprotein-cholesterol (LDL-C)  190 mg/
dL. Moderate or high doses of statin therapy is suggested for
patients with diabetes (age 40–75 years, and serum LDL-C levels of
70–189 mg/dL), having a predicted 10-year atherosclerotic* Corresponding author at: Department of Pharmacology, Lady Hardinge Medical
College and Associated Hospitals, Connaught Place, New Delhi 110001, India.
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creativecommons.org/licenses/by-nc-nd/4.0/).cardiovascular disease risk of 7.5%, without any evidence of
CVD.5 The ASCVD events reduce signiﬁcantly with both moderate
and high intensity statin therapy,5 but low compliance may be a
factor which can negate this outcome.
Compliance is deﬁned as the extent to which a person’s behavior
coincides with medical or health advice.6 A meta-analysis of more
than 90,000 patients demonstrated that statins are the most
effective lipid-modifying agents with a 17–26% reduction in risk of
coronary events.7–10 The beneﬁt of statin therapy on the desired
clinical outcomes may be lost when patients are poorly compliant
to therapy as only 30–40% of patients who are being treated with
statins continue medication after one year.10–12 This aspect needs to
be explored whether patients despite having less compliance
continue to get the beneﬁts of statins in terms of reduction in serum
levels of total cholesterol (TC), low density lipoprotein-cholesterol
(LDL-C), triglycerides (TG), non-HDL-C and increase in high density
lipoprotein-cholesterol (HDL-C) level or not.
Hence, the present study was planned to correlate the extended
serum lipid proﬁle levels and 3-hydroxyl-3-methylglutarylpliance to statin therapy with lipid proﬁle and serum HMGCoA
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moderate and high intensity statin therapy.
2. Methodology
2.1. Subjects
Dyslipidemic Indian patients with age above 18 years, elevated
LDL-C levels (>190 mg/dL in non-diabetics and 70–189 mg/dL in
diabetics) and/or TG levels (>200 mg/dL), and/or low HDL-C levels
(<40 mg/dL) as per ACC–AHA guidelines receiving statin therapy
for any duration were included in the study.5 The patients were
taking either statin or statin ﬁbrate ﬁxed dose combination for
dyslipidemia and antidiabetics if they had diabetes or antihyper-
tensives for hypertension. Patients who had acute coronary
syndrome within the last 3 months, history of hypothyroidism,
pregnancy/lactation and hypersensitivity or intolerance to statins
were excluded from the study.
2.2. Study design
In a prospective observational study information of patients’
personal, demographic and socioeconomic status was recorded. All
the patients received medicines (statins) from the hospital
pharmacy every month for a period of 3 months. They were
assessed for compliance to statins using pill count method at the
end of 3 month.6 Pill count is an indirect method to measure
adherence and is calculated by comparing the number of doses
taken by the patient with the actual number of doses the patient
should have taken.6 Study protocol was approved by the
Institutional Human Ethical Committee, Lady Hardingre Medical
College, New Delhi (vide number ECR/435/Inst/DL/2013). A written
informed consent for participation in the study was taken from all
the enrolled patients.
Statin therapy was categorized into low (simvastatin 10 mg),
moderate (atorvastatin 10, 20 mg and rosuvastatin 5, 10 mg) and
high (atorvastatin 40, 80 mg and rosuvastatin 20 mg) intensity as
per ACC/AHA guidelines for dyslipidemia.5 Patients with a score of
pill count 80% were considered compliant.
The decision to start the statins or to escalate their doses if
required was at the discretion of the attending physician as per
ACC/AHA guidelines for dyslipidemia. Patients whose dose was
modiﬁed from one intensity statin therapy to another with in the
follow up period were excluded from the study analysis.
A 5 mL venous blood sample was collected at the end of
3 months period to estimate extended lipid proﬁle (TC, LDL-C,
HDL-C, TG, ApoA1 and ApoB) and serum HMGCoA-R enzyme levels.
TC, TG, LDL-C and HDL-C were measured by enzymatic assay
calorimeter of Randox Reagents. BMAssay HMGCoA-R (kit number
– 26215,96T), AssayPro ApoA1 (kit number – 02681524) andTable 1
Patients’ demographic characteristics and clinical proﬁle.








52.83  10.93 54.93  7.94 
Gender
Females, N (%)
36 (52.17) 6 (42.8) 
Mean pill count (%) 83 45
Comorbid conditions
Diabetes mellitus, N (%) 57 (82.6) 11 (78.5) 
Hypertension, N (%) 36 (52.17) 4 (28.5) 
Ischemic heart disease, N (%) 4 (5.7) 1 (7.1) 
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measure HMGCoA-R levels. The minimum detectable levels of
HMGCoA-R, ApoA1, ApoB were 0.06 ng/mL, 0.7 mg/mL and
0.0078 mg/mL respectively. ELISA analysis was done by the
investigator.
2.3. Statistical considerations
The compliance data are presented as percentages whereas
lipid proﬁle parameters are presented as mean  standard devia-
tion. Analysis of data of extended lipid proﬁle among the compliant
and non-compliant patients was done using unpaired Student’s t-test.
The Pearson’s correlation analysis was used for correlation of
compliance with lipid proﬁle and serum HMGCoA-R levels. A p
value of less than 0.05 was considered statistically signiﬁcant. The
data was analyzed using SPSS (Statistic package for Social Sciences)
Version 21.0.
3. Results
Out of a total of 200 patients included in the study 101 (50.5%)
were females. The overall mean age of all the patients was
55.15  10.23 years (range, 23–82 years). The mean duration of
prescription for statin at the time of enrollment was
8.6  13.08 months (range, 1–72 months). The frequently associated
co-morbid condition with dyslipidemia among the study patients was
diabetes mellitus (68%) followed by hypertension (47.5%) and
ischemic heart disease (8%) (Table 1).
A total of 105 (52.5%) patients were prescribed atorvastatin
while 95 (47.5%) patients received rosuvastatin daily. Majority
(80%) of the patients received moderate intensity statin therapy
either atorvastatin (10 or 20 mg) or rosuvastatin (5 or 10 mg) while
40 (20%) patients received high intensity statin therapy. None of
the patients received low intensity statin therapy. Twenty-seven
patients (13.5%) were prescribed only statin. Patients with
hypertriglyceridemia received statins and ﬁbrates (7.5%). along
with the medication for comorbid conditions, i.e. antidiabetics
(73%) and antihypertensives (47.5%).
The mean dose of moderate intensity of atorvastatin and
rosuvastatin was 16.66  9.78 mg and 9.41  8.09 mg per day
respectively whereas the mean dose for high intensity treatment
with atorvastatin and rosuvastatin was 40 mg and 20 mg respec-
tively.
Mean pill count score at the end of 3 months was 56.71% (range,
12.2–94.4%) collectively in both moderate and high intensity statin
therapy. With regard to compliance, only 83 (41.5%) patients were
compliant, i.e. with a pill count of 80% to the statins.
Overall, the serum levels of TC, TG, LDL-C and HMGCoA-R in
compliant group were 172.65  28.42 mg/dL, 133.52  28.66 mg/







53.18  10.48 53.8  9.49 66.18  6.6 56.54  10.21
42 (50.6) 51 (56.04) 8 (30.7) 59 (50.4)
68 (81.9) 55 (60.4) 13 (50) 78 (66.6)
40 (48.1) 50 (54.9) 5 (19.2) 55 (47.0)
5 (6.02) 11 (12.08) 0 (0) 11 (9.4)
pliance to statin therapy with lipid proﬁle and serum HMGCoA
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Fig. 1. Comparison of lipid proﬁle levels after 3 months of statin therapy in
compliant and noncompliant patients.
Fig. 2. Comparison of ApoA1, ApoB and HMGCoA-R levels after 3 months of statin
therapy in compliant and non-compliant patients.
Fig. 3. Correlation of HMGCoA-R in moderate and high intensity statin therapy
groups with compliance using pill count.
Fig. 4. Correlation of HMGCoA-R in moderate and high intensity statin therapy
groups with compliance using pill count.
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higher while LDL-C and HMGCoA-R values were signiﬁcantly higher
(Figs. 1 and 2).
The overall levels of total cholesterol (r = 0.709; p = 0.000), TG
(r = 0.475; p = 0.000), LDL-C (r = 0.751; p = 0.000) and ApoA1
(r = 0.327; p = 0.000) were inversely correlated with compliance.Table 2
Correlation of compliance (pill count) in moderate and high intensity statin therapy gr
Intensity of statin TC TG LDL-C 
Moderate intensity
Pearson correlation 0.727 0.565 0.785 
p value 0.000 0.000 0.000 
High intensity
Pearson correlation 0.820 0.086 -0.906 
p value 0.000 0.599 0.000 
Overall
Pearson correlation 0.709 0.475 -0.751 
p value 0.000 0.000 0.000 
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showed similar impact on total cholesterol (r = 0.727; p = 0.000),
TG (r = 0.565; p = 0.000), LDL-C (r = 0.785; p = 0.000) and ApoA1
(r = 0.278; p = 0.000) levels (Table 2). The inhibition of HMGCoA-
R was also inversely correlated with compliance. The inhibition of
HMGCoA-R, TC, LDL-C, ApoA1 was more inversely correlated with
compliance in higher intensity statin therapy than that in
moderate intensity (Table 2).
Levels of LDL-C were between 60 and 80 mg/dL when
compliance to moderate and high intensity statin therapy was
greater than 60% (Fig. 3). To attain these LDL-C levels, statin
therapy reduced the HMGCoA-R enzyme levels to 9–10 ng/mL
thereafter maintaining a plateau despite increase in compliance
(Fig. 4).
4. Discussion
The patients compliant to statin therapy in our study were
41.5%, i.e. with a pill count >80% at the end of 3 months. Ho et al.
reported higher proportion (70–80%) of the patients compliant to
the statins13 and in another study only 60–70% of patients were
compliant.14,15
On the other hand mean pill count of all the subjects in this
study was 56.71% despite 41.5% of the patients being compliant as
most patients had compliance between 20% and 90% with only
1 patient below 20%. Whereas, Perrault et al. reported a higher
mean compliance of 74% during the ﬁrst year and 53% after 1 year
of follow-up.16 Higher cost of statin therapy and higher incidence
of adverse events is known to adversely affect compliance but
those may not be the deterrents for good compliance in our study
as medication was provided free of cost to the patients and also, no
serious or severe adverse events were reported.17 In light of this,
lower education levels leading to inadequate awareness about theoups with lipid proﬁle parameters including HMGCoA-R levels after 3 months.
HDL-C HMGCoA-R ApoA1 ApoB
0.795 0.119 0.278 0.028
0.000 0.000 0.000 0.722
0.768 0.211 0.402 0.382
0.000 0.000 0.010 0.015
0.731 0.111 0.327 0.050
0.000 0.000 0.000 0.495
pliance to statin therapy with lipid proﬁle and serum HMGCoA
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be the factors for lower compliance.18
Virani et al. reported association of high-intensity statin use
with a modest reduction in compliance (proportion of days
covered) when compared with low and moderate-intensity statin
use.19 Similarly, in the present study, slightly lower pill count was
seen in patients on high intensity statin therapy(56.4%) as
compared to those on moderate intensity (56.8%).
In our study, there existed a signiﬁcant inverse correlation
between compliance to statin therapy and serum TC, TG, LDL-C,
ApoA1 and HMGCoA-R levels but it was more inversely correlated
with high intensity statin therapy suggesting an association
between stain intensity and inhibition of enzyme along with
favorable change in lipid parameters. Vodonos et al. reported a
greater reduction in serum LDL-C levels with high intensity statin
as compared to moderate intensity with increase in adherence.20
Since this was the ﬁrst study to correlate serum HMGCoA-R levels
with compliance, so it was not possible to compare these ﬁndings.
In the present study, rise in HDL-C showed a positive correlation
(r = 0.731, p = 0.000) with statin compliance in both moderate and
high intensity statin therapy. On the contrary, Vodonos et al. in a
cross-sectional study, could not demonstrate a rise in HDL-C levels
with an increase in compliance probably due to inclusion of
simvastatin and lovastatin apart from atorvastatin and rosuvas-
tatin as the latter are associated with greater fall in LDL-C and TG
leading to a higher rise in HDL-C levels.20,21
In our study, a plateau in the levels of HMGCoA-R was achieved
when compliance to moderate and high intensity statin therapy
was beyond 60%. Beyond this, the fall in LDL-C levels was not as
much as when compliance was below 60% (Figs. 3 and 4). In this
context, Vodonos et al. also observed a plateau in LDL-C levels
when compliance was more than 80% but they did not estimate
HMGCoA-R levels.20 On this basis, if the patients miss to take few
doses of atorvastatin or rosuvastatin in between, perhaps it may
not compromise their cardiovascular beneﬁts. The optimum
clinical beneﬁt despite poor compliance of statins viz. atorvastatin
and rosuvastatin could be due to their pharmacokinetic (longer
half-life) and pharmacodynamics (active metabolite) properties
which may sufﬁce to inhibit HMGCoA-R enzyme adequately.21 This
ﬁnding also supports the use of every other day dosing of statins to
treat dyslipidemia.22–30
The levels of LDL-C and HMGCoA-R fell with increase in
adherence in both moderate and high intensity statin therapy
(Figs. 3 and 4) suggesting improvement in compliance up to 60%
should be considered. Compliance can be improved by patient
education, patient–physician communication enhancement, ex-
tended care through ancillary health care providers, simpliﬁcation
of drug regimens, and increased patient monitoring and follow-
up.31 Switching to a higher intensity statin therapy may be another
option which needs to be explored further in larger prospective
longitudinal studies.
This study unveils the association and correlation of TC, TG
HDL-C, LDL-C, ApoA1, ApoB and HMGCoA-R levels with compli-
ance of patient to statins. These ﬁndings suggested that estimation
of HMGCoA-R levels in dyslipidemic patients on statins needs to be
explored further as a tool to optimize the statin therapy and guide
the physicians in decision making for dose modiﬁcation and
patients’ counseling for compliance improvement.
5. Conclusion
It is concluded that improvement in compliance to statins up to
60% should be considered along with the option of switching over
to a higher intensity statin. HMGCoA-R may be explored as a tool to
aid physicians in optimizing and individualizing statin therapy.Please cite this article in press as: Grover A, et al. Correlation of com
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